Co-Founder and Partner, 1315 Capital
Adele Oliva brings over 25 years of finance and healthcare experience to 1315 Capital, including 18 years in private equity. Throughout her investing career, she has focused on commercial stage specialty pharmaceutical, medical technology and healthcare service investments.
Ms. Oliva co-founded 1315 Capital in 2014 to establish a firm focused on healthcare growth investing. She was recruited to Quaker Partners, which she joined in 2007, to expand their growth and expansion stage investing practice. Prior to Quaker, Ms. Oliva was Co-Head of US Healthcare at Apax Partners, a global private equity firm, where she started in 1997.
Forbes has recognized Ms. Oliva on its Midas List of top 100 technology investors worldwide, top 10 life science investors and top women in venture capital.
Ms. Oliva has served on the board of many high growth companies including Ascent Healthcare Solutions (acquired by Stryker), EKR Therapeutics (acquired by Cornerstone Therapeutics), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Precision Dermatology (acquired by Valeant), Prometheus Labs (acquired by Nestle) and SkinMedica (acquired by Allergan). She currently serves on the boards of Novasom, Onkos Surgical, TearScience and TelaBio.
Prior to entering private equity as a Kauffman Fellow in 1997, Ms. Oliva built a strong foundation in finance and healthcare at CoreStates in commercial banking and Baxter Healthcare in marketing and business development. Ms. Oliva received a BSc from St. Joseph's University and a MBA from Cornell University, where she was awarded the Albert Fried Fellowship.